A Nature Biotechnology paper introduced an epigenetic editing platform enabling safe, multiplexed gene programming in primary human T cells to enhance CAR‑T potency and manufacturability. The method uses targeted, reversible chromatin edits to reprogram T cells without permanent genomic disruption, offering a route to multi‑gene modulation in adoptive cell therapies. In parallel, a separate report described CAR‑T constructs that target HIV‑linked B‑cell cancers, including preclinical and early clinical insights into efficacy and allogeneic manufacturing approaches. Together, these advances deepen the toolkit for next‑generation cellular immunotherapies and suggest platforms that can be applied across oncology and infectious disease‑linked malignancies.